JP2013515079A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515079A5 JP2013515079A5 JP2012546164A JP2012546164A JP2013515079A5 JP 2013515079 A5 JP2013515079 A5 JP 2013515079A5 JP 2012546164 A JP2012546164 A JP 2012546164A JP 2012546164 A JP2012546164 A JP 2012546164A JP 2013515079 A5 JP2013515079 A5 JP 2013515079A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- seq
- antibody
- pseudomonas aeruginosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28897709P | 2009-12-22 | 2009-12-22 | |
| US61/288,977 | 2009-12-22 | ||
| PCT/US2010/061636 WO2011087799A1 (en) | 2009-12-22 | 2010-12-21 | A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013515079A JP2013515079A (ja) | 2013-05-02 |
| JP2013515079A5 true JP2013515079A5 (enExample) | 2014-05-29 |
Family
ID=44224810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546164A Pending JP2013515079A (ja) | 2009-12-22 | 2010-12-21 | 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8642039B2 (enExample) |
| EP (1) | EP2515935A4 (enExample) |
| JP (1) | JP2013515079A (enExample) |
| CA (1) | CA2784033A1 (enExample) |
| WO (1) | WO2011087799A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2097107B1 (en) * | 2006-10-25 | 2016-05-04 | Revalesio Corporation | Therapeutic treatment of eyes using an oxygen-enriched solution |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US20100310665A1 (en) * | 2007-10-25 | 2010-12-09 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
| US20090263495A1 (en) * | 2007-10-25 | 2009-10-22 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| MX2012012971A (es) | 2010-05-07 | 2013-02-07 | Revalesio Corp | Composiciones y metodos para mejorar el rendimiento fisiologico y el tiempo de recuperacion. |
| MX2013001636A (es) | 2010-08-12 | 2013-05-01 | Revalesio Corp | Composiciones y metodos para el tratamiento de taupatias |
| DK2718320T3 (en) | 2011-06-10 | 2018-03-26 | Medimmune Ltd | ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF |
| US10597439B2 (en) | 2011-11-07 | 2020-03-24 | Medimmune Limited | Combination therapies using anti-pseudomonas PSL and PCRV binding molecules |
| TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| NZ774893A (en) | 2015-05-01 | 2024-11-29 | Inhibrx Biosciences Inc | Type iii secretion system targeting molecules |
| WO2020185986A1 (en) | 2019-03-13 | 2020-09-17 | Medimmune, Llc | Decreasing staphylococcus aureus infections in colonized patients |
| CN114072145B (zh) * | 2020-06-01 | 2024-06-11 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别假单胞菌pcrv的抗体及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000033872A2 (en) | 1998-11-25 | 2000-06-15 | Mcw Research Foundation, Inc. | Method of and compositions for immunization with the pseudomonas v antigen |
| SI2266534T1 (sl) * | 2004-05-17 | 2012-12-31 | Gilead Sciences, Inc. | Aerosolizirana kombinacija fosfomicin/tobramicin za zdravljenje cistične fibroze |
| US20060228384A1 (en) * | 2005-04-06 | 2006-10-12 | Sequoia Sciences, Inc. | Control of biofilm with a biofilm inhibitor |
| US8268347B1 (en) * | 2006-10-24 | 2012-09-18 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US20100282247A1 (en) * | 2007-09-25 | 2010-11-11 | Novartis Ag | Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin |
| CN101910197B (zh) * | 2007-11-30 | 2014-09-24 | 卡罗拜奥斯制药公司 | 针对铜绿假单胞菌pcrv抗原的抗体 |
| EP2393515A1 (en) | 2009-02-04 | 2011-12-14 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
-
2010
- 2010-12-21 CA CA2784033A patent/CA2784033A1/en not_active Abandoned
- 2010-12-21 US US12/975,214 patent/US8642039B2/en not_active Expired - Fee Related
- 2010-12-21 EP EP10843547.0A patent/EP2515935A4/en not_active Withdrawn
- 2010-12-21 JP JP2012546164A patent/JP2013515079A/ja active Pending
- 2010-12-21 WO PCT/US2010/061636 patent/WO2011087799A1/en not_active Ceased